Back

The Impacts of Oral Anticoagulants on Clinical Outcomes in Patients with Atrial Fibrillation Across Five Stages of Renal Function

Liao, J.-N.; Chan, Y.-H.; Lee, H.-F.; Yeh, Y.-H.; Chang, S.-H.; Chen, S.-A.; Chao, T.-F.

2024-04-16 cardiovascular medicine
10.1101/2024.04.15.24305865 medRxiv
Show abstract

BackgroundTo analyze the impact of using different renal function equations and stroke prevention strategy in atrial fibrillation (AF) across all chronic kidney disease (CKD) stages. MethodsWe used the Cockcroft-Gault (CG), Modified Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations to classify 39,217 patients into stage 1 to 5 CKD during July 1st, 2001, and September 30st, 2018. The endpoint is a composite outcome including ischemic stroke or major bleeding or mortality. ResultsMore patients belonged to stage 1 and 2 CKD using the MDRD and CKD-EPI equations. In subgroups of patients with eGFR-MDRD or eGFR-CKD-EPI [&ge;] 60 mL/min, a 17-18% increase of event was observed in patients with eGFR-CG < 60 mL/min compared to those [&ge;] 60 mL/min. Compared to no oral anticoagulant (OAC), OAC use was associated with a significantly lower risk of event across stage 1 to 4 CKD but not in stage 5 CKD. Both warfarin and NOACs exhibited better outcome compared to no OAC across stage 1 to 4 CKD while NOACs was associated with more risk reduction compared to warfarin. Among patients on OACs, there was a trend toward better outcome with NOAC than warfarin across stage 2-4 CKD but not in stage 1 and 5 CKD. ConclusionsOAC should be used in stage 1 to 4 CKD with NOAC exhibiting the trend of better outcome through stage 2 to 4 CKD than warfarin. For stage 5 CKD, optimal strategy remains undetermined. Clinical PerspectiveO_LIWhat Is New? The stages of renal function of AF patients varied significantly with different renal equations, and tthe CG equation remained effective in differentiating clnical outcomes for patients with eGFR-MDRD [&ge;] 60 mL/min or eGFR-CKD-EPI [&ge;] 60 mL/min C_LIO_LIWhat Are the Clinical Implications? OAC should be used in stage 1 to 4 CKD with NOAC exhibiting the trend of better outcome through stage 2 to 4 CKD than warfarin. C_LI

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.